Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Immunoreceptor tyrosine-based activation motif (ITAM) is a sequence motif (consensus signature: YxxL/Ix_6–8_YxxL/I) repeated twice within the cytoplasmic domains of various immune receptors (e.g., CD3 chains of TCR, CD79 chains of BCR, Fc receptors, DAP12, FcRγ)[1][3][5]. Upon ligand engagement, ITAM tyrosines are phosphorylated by Src-family kinases. Phosphorylated ITAMs recruit SH2-domain proteins (notably Syk and ZAP-70 kinases), initiating intracellular signaling cascades resulting in immune cell activation, proliferation, and differentiation[1][3][5]. ITAMs are essential for adaptive immunity and are also involved in specialized functions such as osteoclast differentiation[4]. Aberrant ITAM signaling plays a role in autoimmune diseases, inflammation (e.g., rheumatoid arthritis), infection, and oncogenesis[4][6]. Therapeutic approaches typically target ITAM-associated receptors or signaling pathways, not the ITAM motif itself.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoreceptor tyrosine-based activation motif (ITAM).